NASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free BMEA Stock Alerts $11.00 -0.13 (-1.17%) (As of 05/24/2024 08:49 PM ET) Add Compare Share Share Today's Range$10.73▼$11.6050-Day Range$10.47▼$17.0052-Week Range$8.13▼$43.69Volume1.05 million shsAverage Volume921,045 shsMarket Capitalization$395.40 millionP/E RatioN/ADividend YieldN/APrice Target$53.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Biomea Fusion alerts: Email Address Biomea Fusion MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside384.1% Upside$53.25 Price TargetShort InterestBearish50.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.20) to ($3.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.72 out of 5 starsMedical Sector654th out of 922 stocksPharmaceutical Preparations Industry296th out of 421 stocks 3.4 Analyst's Opinion Consensus RatingBiomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBiomea Fusion has only been the subject of 4 research reports in the past 90 days.Read more about Biomea Fusion's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted50.32% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 14, which indicates bearish sentiment.Change versus previous monthShort interest in Biomea Fusion has recently increased by 1.09%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BMEA. Previous Next 2.7 News and Social Media Coverage News SentimentBiomea Fusion has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biomea Fusion this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders27.57% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biomea Fusion's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biomea Fusion are expected to grow in the coming year, from ($4.20) to ($3.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biomea Fusion's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself About Biomea Fusion Stock (NASDAQ:BMEA)Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Read More BMEA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMEA Stock News HeadlinesMay 3, 2024 | investorplace.comBMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024May 2, 2024 | finance.yahoo.comBiomea Fusion Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 1, 2024 | globenewswire.comBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | msn.com3 Best Stocks to Buy Now, 4/4/2024, According to Top AnalystsApril 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Results and Strong Financial PositionApril 1, 2024 | globenewswire.comBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | investorplace.comBMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023April 1, 2024 | benzinga.comRecap: Biomea Fusion Q4 EarningsApril 1, 2024 | globenewswire.comBiomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219April 1, 2024 | globenewswire.comBiomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsMarch 17, 2024 | finance.yahoo.comBMEA Apr 2024 5.000 putMarch 17, 2024 | finance.yahoo.comBMEA Apr 2024 5.000 callMarch 7, 2024 | investorplace.com7 Short-Squeeze Stocks That Could Send the Bears Into Panic-ModeMarch 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)March 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Trial Outcomes and Strong Safety ProfileMarch 6, 2024 | finance.yahoo.comBiomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionMarch 6, 2024 | globenewswire.comBiomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionMarch 1, 2024 | markets.businessinsider.comBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | globenewswire.comBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)February 27, 2024 | seekingalpha.comWhy Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology ResearchFebruary 19, 2024 | markets.businessinsider.comFeeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch ForFebruary 18, 2024 | investorplace.com3 Speculative Stocks That Could Make Your February UnforgettableFebruary 7, 2024 | markets.businessinsider.comDissecting My Biomea Fusion (NASDAQ:BMEA) Options Trade: Tips, Tricks, and Lessons LearnedJanuary 10, 2024 | theglobeandmail.comWall Street Expects 190% Upside for This Biotech StockJanuary 9, 2024 | finanznachrichten.deBiomea Fusion, Inc.: Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219See More Headlines Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/26/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BMEA CUSIPN/A CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$53.25 High Stock Price Target$90.00 Low Stock Price Target$15.00 Potential Upside/Downside+384.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.88% Return on Assets-60.44% Debt Debt-to-Equity RatioN/A Current Ratio5.84 Quick Ratio5.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.76 per share Price / Book2.93Miscellaneous Outstanding Shares35,945,000Free Float26,035,000Market Cap$395.40 million OptionableOptionable Beta-0.33 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Thomas Andrew Butler (Age 43)Co-Founder, Chairman & CEO Comp: $950.41kMr. Ramses M. Erdtmann (Age 61)Co-Founder, President, COO & Director Mr. Franco Valle (Age 43)CFO & Principal Accounting Officer Comp: $673.66kDr. Juan Pablo Frias M.D.Chief Medical OfficerMr. Heow Tan (Age 65)Chief Technology & Quality Officer Ms. Naomi CretcherChief People OfficerDr. Thorsten Kirschberg Ph.D. (Age 54)Executive Vice President of Chemistry Dr. Stephan Morris M.D.Chief Development OfficerMr. Ravi UpasaniExecutive Vice President of Intellectual PropertyCaroline Perez- DupontSenior Vice President of ContractsMore ExecutivesKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXErascaNASDAQ:ERASMereo BioPharma GroupNASDAQ:MREOAcelyrinNASDAQ:SLRNTerns PharmaceuticalsNASDAQ:TERNView All CompetitorsInsiders & InstitutionsIkarian Capital LLCSold 397,000 shares on 5/17/2024Ownership: 0.000%Walleye Trading LLCBought 100 shares on 5/17/2024Ownership: 0.000%Janus Henderson Group PLCSold 432,967 shares on 5/16/2024Ownership: 3.576%Bayesian Capital Management LPBought 27,041 shares on 5/16/2024Ownership: 0.075%California State Teachers Retirement SystemSold 1,042 shares on 5/16/2024Ownership: 0.064%View All Insider TransactionsView All Institutional Transactions BMEA Stock Analysis - Frequently Asked Questions Should I buy or sell Biomea Fusion stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BMEA shares. View BMEA analyst ratings or view top-rated stocks. What is Biomea Fusion's stock price target for 2024? 7 brokers have issued 1-year target prices for Biomea Fusion's stock. Their BMEA share price targets range from $15.00 to $90.00. On average, they predict the company's share price to reach $53.25 in the next year. This suggests a possible upside of 384.1% from the stock's current price. View analysts price targets for BMEA or view top-rated stocks among Wall Street analysts. How have BMEA shares performed in 2024? Biomea Fusion's stock was trading at $14.52 at the beginning of the year. Since then, BMEA shares have decreased by 24.2% and is now trading at $11.00. View the best growth stocks for 2024 here. When is Biomea Fusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our BMEA earnings forecast. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) posted its earnings results on Thursday, May, 2nd. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.02) by $0.07. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $120 million in an initial public offering on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Biomea Fusion's major shareholders? Biomea Fusion's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.80%), Janus Henderson Group PLC (3.58%), Price T Rowe Associates Inc. MD (0.49%), Ikarian Capital LLC (0.00%), Simplex Trading LLC (0.00%) and Griffin Asset Management Inc. (0.11%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Michael JM Hitchcock and Rainer M Erdtmann. View institutional ownership trends. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BMEA) was last updated on 5/27/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsWARNING about the death of the U.S. dollar…Colonial MetalsA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
